Previous Page  26 / 27 Next Page
Information
Show Menu
Previous Page 26 / 27 Next Page
Page Background

stroma predicts benefit to

pembrolizumab in bladder cancer

0

20

40

60

80

100

pT0

Non-pT0

PD-L1 CPS (%)

Figure S3

-2

0

2

4

6

5

10

15

20

Figure S4

TMB (mutations/Mb)

Log (odds ratio)

provided in the Data Supplement). In addition, tumors that

harbored

PBRM1

mutations had signi

fi

cantly higher median TMB

values than did those without them (16.7 mut/Mb

v

10.5 mut/Mb;

P

= .001). The logistic model could not be applied as a result of the

small numbers.

Gene expression analyses demonstrated that 18 of 22 genes

from pT0 patients had signi

fi

cantly higher expressions in pre-

therapy lesions compared with those from pT

$

2 patients (Data

Supplement). Informative genes were those involved in interferon

gamma signaling, antigen presentation (HLA molecules and

immunoproteasome subunits), T-cell functional differentiation to

cytolytic effectors, chemokines and chemokine receptors, in-

hibitory receptors and ligands, and the immunosuppressive gene

IDO1

.

Fourteen patients among those with a postpembrolizumab

pT2 stage tumor or higher had paired tissue samples that were

evaluable for comparison after quality check. Postpembrolizumab

Table 3.

Pathologic Response to Pembrolizumab

Response

All Treated

Patients

(N = 50)

PD-L1 CPS

$

10% (n = 35)

PD-L1 CPS

,

10% (n = 15)

Primary end point

Pathologic complete

response, No. (%)

21 (42)

19 (54.3)

2 (13.3)

95% CI

28.2 to 56.8

Secondary end point

Pathologic

downstaging

to pT

,

2, No. (%)

27 (54)

23 (65.7)

4 (26.7)

95% CI*

39.3 to 68.2

Treatment failure, No. (%)

pT2N0

2 (3.8)

pT3-4N0

6 (12)

pTanyN+

10 (20)

Additional MVAC

chemotherapy

5 (10)

RECIST v1.1 PD

0

Necchi et al

Necchi, A et al, J Clin Oncol 2018

Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With

Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm,

Phase II Study N=50

ü

pT0 was achieved in 19 patients (54.3%) with PD-L1 CPS ≥10% compared with 2 patients

(13.3%) with CPS <10% (P = .011)

ü

A significant (P = .022) nonlinear association between TMB and pT0 response was found

(cutoff TMB > 15 mut/Mb)